Giulio Marchesini

Zitiert von

	Alle	Seit 2019
Zitate	88095	38410
h-index	115	72
i10-index	416	280

8000

4000

2000

6000

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024221 242 311 489 663 1081 1371 1599 1880 2034 2225 2515 2840 3023 3139 3417 3576 4919 5371 5945 6186 7199 7766 7571 7375 2266

Öffentlicher Zugriff

Alle anzeigen

35 Artikel

3 Artikel

verfügbar

nicht verfügbar

Basierend auf Fördermandaten

Koautoren

Giampaolo BianchiUniversità di BolognaBestätigte E-Mail-Adresse bei unibo.it
Riccardo Dalle GraveVilla Garda Hospital, Department of Eating and Weight DisordersBestätigte E-Mail-Adresse bei adacentroobesitaanoressia.it
Salvatore PettaRicercatore di Gastroenterologia, Università di PalermoBestätigte E-Mail-Adresse bei unipa.it
Maria Letizia PetroniUniversity of BolognaBestätigte E-Mail-Adresse bei unibo.it
Antonio CraxiFull Professor of Gastroenterology and Internal Medicine, PROMISE, University of Palermo, ItalyBestätigte E-Mail-Adresse bei unipa.it
Calogero CammàSection of Gastroenterology, University of PalermoBestätigte E-Mail-Adresse bei unipa.it
Luca ValentiAssociate Professor of Internal Medicine, Università degli Studi di Milano, Fondazione Ca' GrandaBestätigte E-Mail-Adresse bei unimi.it
C DayNewcastle UniversityBestätigte E-Mail-Adresse bei ncl.ac.uk
Licata AnnaAssociate Professor of Internal MedicineBestätigte E-Mail-Adresse bei unipa.it
Zobair YounossiThe Global NASH CouncilBestätigte E-Mail-Adresse bei cldq.org
Amalia GastaldelliInstitute of Clinical Physiology, CNRBestätigte E-Mail-Adresse bei cnr.it
Helena Cortez-PintoClínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de LisboaBestätigte E-Mail-Adresse bei medicina.ulisboa.pt
Luca MieleFondazione Pol. Univ. A. Gemelli IRCCS, Università Cattolica Sacro Cuore. RomaBestätigte E-Mail-Adresse bei policlinicogemelli.it
Amedeo LonardoMedicina Interna USL ModenaBestätigte E-Mail-Adresse bei ausl.mo.it
Giovanni TargherFull Professor of Endocrinology and Diabetes, University of VeronaBestätigte E-Mail-Adresse bei univr.it
Compare AngeloUniversità di BergamoBestätigte E-Mail-Adresse bei unibg.it
Edoardo MannucciDirettore Agenzia Diabetologia, AOU Careggi, FirenzeBestätigte E-Mail-Adresse bei unifi.it
Quentin M. AnsteeProfessor of Experimental Hepatology, Newcastle University, UKBestätigte E-Mail-Adresse bei newcastle.ac.uk
Fabrizio De PontiProfessor of Pharmacology, University of BolognaBestätigte E-Mail-Adresse bei unibo.it
Riccardo BonadonnaFull Professor of Endocrinology and Metabolism, University of Parma, ItalyBestätigte E-Mail-Adresse bei unipr.it

Folgen

Giulio Marchesini

Professor of Medicine, University of Bologna

Bestätigte E-Mail-Adresse bei unibo.it

metabolism liver diabetes obesity


Titel Nach Zitationen sortieren Nach Jahr sortieren Nach Titel sortieren	Zitiert von Zitiert von	Jahr
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, ... New England Journal of Medicine 373 (22), 2117-2128, 2015	12118	2015
Empagliflozin and progression of kidney dsease in type 2 diabetes C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ... New england journal of medicine 375 (4), 323-334, 2016	3824	2016
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome G Marchesini, E Bugianesi, G Forlani, F Cerrelli, M Lenzi, R Manini, ... Hepatology 37 (4), 917-923, 2003	3605	2003
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ... Hepatology 45 (4), 846-854, 2007	3417	2007
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome G Marchesini, M Brizi, G Bianchi, S Tomassetti, E Bugianesi, M Lenzi, ... Diabetes 50 (8), 1844-1850, 2001	3384	2001
EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease G Marchesini, CP Day, JF Dufour, A Canbay, V Nobili, V Ratziu, H Tilg, ... Journal of Hepatology 64 (6), 1388-1402, 2016	2499*	2016
EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease EA the Study of the Liver (EASL), EA the Study of Diabetes (EASD), ... Journal of Hepatology 64 (6), 1388-1402, 2016	2487*	2016
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease European Association for The Study of The Liver, ... Obesity facts 9 (2), 65-90, 2016	2487	2016
Association of nonalcoholic fatty liver disease with insulin resistance G Marchesini, M Brizi, AM Morselli-Labate, G Bianchi, E Bugianesi, ... The American journal of medicine 107 (5), 450-455, 1999	2221	1999
A randomized, controlled trial of 3.0 mg of liraglutide in weight management X Pi‑Sunyer, A Astrup, K Fujioka, F Greenway, A Halpern, M Krempf, ... New England Journal of Medicine 373 (1), 11-22, 2015	2075	2015
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma E Bugianesi, N Leone, E Vanni, G Marchesini, F Brunello, P Carucci, ... Gastroenterology 123 (1), 134-140, 2002	1876	2002
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study G Bedogni, L Miglioli, F Masutti, C Tiribelli, G Marchesini, S Bellentani Hepatology 42 (1), 44-52, 2005	1858	2005
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018	1520	2018
A position statement on NAFLD/NASH based on the EASL 2009 special conference V Ratziu, S Bellentani, H Cortez-Pinto, C Day, G Marchesini Journal of hepatology 53 (2), 372-384, 2010	1443	2010
Insulin resistance: a metabolic pathway to chronic liver disease E Bugianesi, AJ McCullough, G Marchesini Hepatology 42 (5), 987-1000, 2005	1134	2005
Metformin in non-alcoholic steatohepatitis G Marchesini, G Bianchi, S Tomassetti, M Zoli, N Melchionda The Lancet 358 (9285), 893-894, 2001	1089	2001
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019	1044	2019
Clinical features and natural history of nonalcoholic steatosis syndromes Y Falck-Ytter, ZM Younossi, G Marchesini, AJ McCullough Seminars in liver disease 21 (01), 017-026, 2001	1024	2001
A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease E Bugianesi, E Gentilcore, R Manini, S Natale, E Vanni, N Villanova, ... The American journal of gastroenterology 100 (5), 1082, 2005	1004	2005
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes AL Fracanzani, L Valenti, E Bugianesi, M Andreoletti, A Colli, E Vanni, ... Hepatology 48 (3), 792-798, 2008	868	2008

Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.

Artikel 1–20

Zitate pro Jahr

Doppelte Zitate

Zusammengeführte Zitate

Koautor hinzufügenKoautoren

Folgen

Zitiert von

Koautoren